Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

conmed corp. - CNMD

CNMD

Close Chg Chg %
39.62 0.54 1.36%

Closed Market

40.16

+0.54 (1.36%)

Volume: 149.92K

Last Updated:

Dec 24, 2025, 12:59 PM EDT

Trade Now

Company Overview: conmed corp. - CNMD

CNMD Key Data

Open

$39.80

 Day Range

39.73 - 40.36

52 Week Range

38.32 - 74.63

 Market Cap

$1.23B

Shares Outstanding

30.97M

 Public Float

30.02M

Beta

0.98

 Rev. Per Employee

N/A

P/E Ratio

19.51

 EPS

$2.07

Yield

199.15%

 Dividend

$0.20

EX-DIVIDEND DATE

Sep 15, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

617.18K

  

CNMD Performance

1 Week
 
 0.55%
 
1 Month
 
 -7.49%
 
3 Months
 
 -12.67%
 
1 Year
 
 -43.12%
 
5 Years
 
 -64.39%
 

CNMD Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 6
Full Ratings ➔

About conmed corp. - CNMD

CONMED Corp. is a medical technology company, which engages in providing devices and equipment for surgical procedures. Its products include AirSeal and insufflation, allograft cartilage and tissue, arthroplasty, biliary and endoscopic ultrasound, biomedical sensors and electrodes, biopsy and polypectomy, dilators and accessories, electrosurgical units, fixation devices, hemostasis, implants and suture anchors, infection prevention, patient positioning, and related products. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Largo, FL.

CNMD At a Glance

CONMED Corp.
11311 Concept Boulevard
Largo, Florida 33773
Phone 1-727-392-6464 Revenue 1.30B
Industry Medical Specialties Net Income 132.42M
Sector Health Technology 2024 Sales Growth 4.978%
Fiscal Year-end 12 / 2025 Employees 3,900
View SEC Filings

CNMD Valuation

P/E Current 19.443
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 16.099
Price to Sales Ratio 1.636
Price to Book Ratio 2.197
Price to Cash Flow Ratio 12.77
Enterprise Value to EBITDA 14.173
Enterprise Value to Sales 2.345
Total Debt to Enterprise Value 0.31

CNMD Efficiency

Revenue/Employee 334,033.333
Income Per Employee 33,954.615
Receivables Turnover 5.48
Total Asset Turnover 0.566

CNMD Liquidity

Current Ratio 2.301
Quick Ratio 1.054
Cash Ratio 0.088

CNMD Profitability

Gross Margin 53.317
Operating Margin 12.606
Pretax Margin 12.514
Net Margin 10.165
Return on Assets 5.75
Return on Equity 14.739
Return on Total Capital 6.934
Return on Invested Capital 7.123

CNMD Capital Structure

Total Debt to Total Equity 98.387
Total Debt to Total Capital 49.594
Total Debt to Total Assets 41.069
Long-Term Debt to Equity 97.472
Long-Term Debt to Total Capital 49.132
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Conmed Corp. - CNMD

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
1.02B 1.03B 1.24B 1.30B
Sales Growth
+18.08% +1.41% +20.44% +4.98%
Cost of Goods Sold (COGS) incl D&A
477.31M 502.37M 597.89M 608.16M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
49.79M 49.76M 51.40M 51.30M
Depreciation
16.49M 16.05M 16.20M 16.61M
Amortization of Intangibles
33.30M 33.70M 35.20M 34.70M
COGS Growth
+14.19% +5.25% +19.01% +1.72%
Gross Income
538.75M 528.02M 643.07M 694.57M
Gross Income Growth
+21.76% -1.99% +21.79% +8.01%
Gross Profit Margin
+53.02% +51.24% +51.82% +53.32%
2021 2022 2023 2024 5-year trend
SG&A Expense
422.32M 444.39M 512.28M 530.35M
Research & Development
43.56M 47.15M 52.60M 54.43M
Other SG&A
378.76M 397.24M 459.68M 475.92M
SGA Growth
+15.48% +5.23% +15.28% +3.53%
Other Operating Expense
- - - -
-
Unusual Expense
3.82M 141.61M 18.81M (30.69M)
EBIT after Unusual Expense
112.60M (57.98M) 111.97M 194.92M
Non Operating Income/Expense
(4.01M) 16.02M 8.63M 5.41M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
35.48M 28.91M 39.77M 37.30M
Interest Expense Growth
-19.45% -18.54% +37.61% -6.23%
Gross Interest Expense
35.48M 28.91M 39.77M 37.30M
Interest Capitalized
- - - -
-
Pretax Income
73.11M (70.86M) 80.83M 163.03M
Pretax Income Growth
+4,460.51% -196.93% +214.06% +101.70%
Pretax Margin
+7.19% -6.88% +6.51% +12.51%
Income Tax
10.56M 9.72M 16.37M 30.61M
Income Tax - Current - Domestic
512.00K 1.68M 5.89M 6.96M
Income Tax - Current - Foreign
7.05M 14.08M 9.78M 11.45M
Income Tax - Deferred - Domestic
4.92M (5.73M) 1.93M 11.03M
Income Tax - Deferred - Foreign
(1.91M) (310.00K) (1.23M) 1.17M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
62.54M (80.58M) 64.46M 132.42M
Minority Interest Expense
- - - -
-
Net Income
62.54M (80.58M) 64.46M 132.42M
Net Income Growth
+557.16% -228.84% +179.99% +105.44%
Net Margin Growth
+6.16% -7.82% +5.19% +10.17%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
62.54M (80.58M) 64.46M 132.42M
Preferred Dividends
- - - -
-
Net Income Available to Common
62.54M (80.58M) 64.46M 132.42M
EPS (Basic)
2.1446 -2.6825 2.1018 4.293
EPS (Basic) Growth
+544.02% -225.08% +178.35% +104.25%
Basic Shares Outstanding
29.16M 30.04M 30.67M 30.85M
EPS (Diluted)
1.9413 -2.6825 2.0432 4.2511
EPS (Diluted) Growth
+501.02% -238.18% +176.17% +108.06%
Diluted Shares Outstanding
32.22M 30.04M 31.55M 31.15M
EBITDA
166.22M 133.38M 182.19M 215.53M
EBITDA Growth
+28.83% -19.76% +36.59% +18.30%
EBITDA Margin
+16.36% +12.94% +14.68% +16.54%

Snapshot

Average Recommendation HOLD Average Target Price 50.20
Number of Ratings 6 Current Quarters Estimate 1.324
FY Report Date 12 / 2025 Current Year's Estimate 4.501
Last Quarter’s Earnings 1.08 Median PE on CY Estimate N/A
Year Ago Earnings 4.17 Next Fiscal Year Estimate 4.463
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 6 5 6 6
Mean Estimate 1.32 0.94 4.50 4.46
High Estimates 1.33 1.00 4.51 4.95
Low Estimate 1.31 0.88 4.48 4.15
Coefficient of Variance 0.64 5.22 0.27 7.92

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 5 5 5
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Hold Hold Hold

Insider Actions for Conmed Corp. - CNMD

Date Name Shares Transaction Value
Nov 25, 2025 Richard Glaze Chief Information Officer N/A Open market or private sale of non-derivative or derivative security Non-derivative transaction at $41.21 per share 0.00
Sep 10, 2025 Kim Kelderman Director 500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 10, 2025 Kim Kelderman Director 6,227 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 9, 2025 Todd W. Garner Executive Vice President & CFO 598 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $57.37 per share 34,307.26
Apr 7, 2025 Brent Lalomia Executive VP RA, QA 94 Other acquisition or disposition Non-derivative transaction at $68.44 per share 6,433.36
Mar 12, 2025 Brent Lalomia Vice President QA and RA 1,006 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $62.74 per share 63,116.44
Mar 12, 2025 Brent Lalomia Vice President QA and RA 75 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2025 Pete K. Shagory EVP, STRAT & CORP DEVT 26,127 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Johonna Pelletier Treasurer and VP, Tax 9,300 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 John Ferrell Executive Vice President - HR 21,516 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Edward A. Clifford VP Global Manufacturing 26,127 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Hollie K. Foust General Counsel & Corp Sec 30,738 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 26, 2025 Mark B. Kaye Director 1,846 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 26, 2025 Mark B. Kaye Director 152 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Conmed Corp. in the News